Pfizer (PFE)

Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company attributed the performance to increased Sanofi collaboration revenue and continued growth from DUPIXENT,

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

The stocks listed here yield up to 5.8%.

These three high-yield dividend stocks could surge once investors realize they've overreacted to recent headwinds.

Pfizer has a plan to bounce back from recent obstacles.

Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.

One of these pharma stocks offers more income, but the other offers a safer dividend.

Here's how pharmaceutical stocks compare to biotech in terms of risk, rewards, and costs.

Prelude Therapeutics (NASDAQ:PRLD) outlined progress across three priority programs at a Chardan Capital investor session, emphasizing its recently initiated JAK2 program, an IND-cleared KAT6A degrader for breast cancer and a mutant calreticulin, or mCALR, program for myeloproliferative neoplasms.

They definitely matter... up to a point.

Pfizer's revenue swung sharply lower before stabilizing, while Bristol Myers Squibb kept climbing steadily—a divergence that matters for long-term investors.

Biotech and pharma stocks, tracked by the iShares Biotechnology ETF, have shown relative strength amid the tech sell-off, with Eli Lilly and Pfizer standing out as top performers.

This company made headlines with its coronavirus vaccine.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical...

The stock has outperformed the market this year, and it still looks heavily undervalued.

It has been a volatile year for the biotech.

Not every company is at risk.

These five high-yield dividend stocks are paying yields of 5.88% to 16.72% -- but beware of a few key risks.

The gene-editing biotech stock is down more than 12% this year.

BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials.

You'd need to invest over $200,000 in the pharma leader at its current price.

Pfizer's dividend yield is attractive, but investors need to know if it can maintain it.